Prevalence and Clinical Significance of high Residual Platelet Reactivity in Patients with Unstable Angina
Abstract
Patients with UA with different treatment strategies had a fairly high percentage of detected resistance to antiplatelet agents: 1G-26,4%, 2G-45,6%, 3G - 47% which in the future (within 18 months of observation)resulted in the development of recurrent coronary events. Cardiovascular complications occurred in 38 individuals (29,9%) with UA within 18 months follow-up, of whom 29 patients had high residual platelet reactivity. The risk of recurrent coronary events in patients with high residual platelet reactivity is significantly higher than in patients sensitive to antiplatelet agents: relative risk RR=5,5; confidence interval [95% CI of 2.7-19]; p=0.0001. Simul¬taneous resistance to clopidogrel and acetylsalicylic acid (ASA) was detected in 6.3% of patients which was associated with a high risk of repeated coronary events within 18 months of observation (r=0.74; p=0.0002), while the relative risk was RR=8.9 in comparison with patients with good sensitivity to antiplatelet agents; confidence interval [95% CI 6,7-31]; p=0.0001.
About the Authors
L. G. Gelis
Scientific and Practical Center of Cardiology of the Republic of Belarus
Belarus
Belarus
E. A. Medvedeva
Scientific and Practical Center of Cardiology of the Republic of Belarus
Belarus
Belarus
I. I. Russkih
Scientific and Practical Center of Cardiology of the Republic of Belarus
Belarus
Belarus
References
1. Vorob'eva I.I., Rizhkova E. V., Vasil'eva E.YU., SHpektor A. V. Vliyanie sistemnogo vospaleniya na effekt antiagregantnoi terapii u bol'nih s ostrim koronarnim sindromom [Influence of systemic inflammation on the effect of antiplatelet therapy in patients with acute coronary syndrome]. Kreativnaya kardiologiya, 2012, no. 1, pp. 5-14. (in Russian).
2. Andreev D. A. Rol' testirovaniya funktsional'noi aktivnosti trombotsitov v profilaktike serdechno-sosudistih oslozhnenii u bol'nih, poluchayuschih antitrombotsitarnuyu terapiyu [The role of testing the functional activity of platelets in the prevention of cardiovascular complications in patients receiving antiplatelet therapy]. Ratsional'naya Farmakoterapiya v Kardiologii, 2014, vol. 10, no. 6, pp. 679-687. (in Russian).
3. Puchin'yan N.F., Furman N. V., Dolotovskaya P. V., Malinova L. I. Visokaya ostatochnaya reaktivnost' trombotsitov na fone dvoinoi antiagregantnoi terapii, viyavlennaya metodom opticheskoi agregatometrii, i chastota razvitiya aterotromboticheskih oslozhnenii posle stentirovaniya koronarnih arterii u bol'nih ishemicheskoi bolezn'yu serdtsa v real'noi klinicheskoi praktike [High residual reactivity of platelets against a background of dual antiplatelet therapy, revealed by the method of optical aggregation, and the frequency of development of atherothrombotic complications after coronary artery stenting in patients with coronary heart disease in real clinical practice]. Ratsional'naya Farmakoterapiya v Kardiologii, 2016, vol. 12, no. 4, pp. 385-390. (in Russian).
4. Straub N., Beivers A., Lenk E., Aradi D., Sibbing D. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients. Thromb. Haemost, 2014, vol. 111, no. 2. pp. 290-299.
5. Price M. J., Berger P. B., Teirstein P. S., Tanguay J. F., Angiolillo D. J., Spriggs D., Puri S., Robbins M., Garratt K. N., Bertrand O. F., Stillabower M. E., Aragon J. R., Kandzari D. E., Stinis C. T., Lee M. S., Manoukian S. V., Cannon C. P., Schork N. J., Topol E. J., GRAVITAS Investigators Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA, 2011, vol. 305, no. 11, pp. 1097-1105.
6. Mirzaev K. B., Andreev D. A., Sichev D. A. Otsenka agregatsii trombotsitov v klinicheskoi praktike [Evaluation of platelet aggregation in clinical practice]. Ratsional'naya Farmakoterapiya v Kardiologii, 2015, vol. 11, no. 1, pp. 85-91. (in Russian).
7. Gelis L. G., Medvedeva E. A., Markova I. A., Russkih I. I., Kolyadko M. G. Klinicheskie posledstviya rezistentnosti k antitrombotsitarnim preparatam u lits, perenesshih nestabil'nuyu stenokardiyu [Clinical consequences of resistance to antiplatelet drugs in people who have undergone unstable angina]. Kardiologiya v Belarusi, 2015, vol. 3, no. 40, pp. 78-88. (in Russian).
8. Sibbing D., Morath T., Braun S., Stegherr J., Mehilli J., Vogt W., Schomig A., Kastrati A., von Beckerath N. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb. Haemost, 2010, vol. 103, no 1, pp. 151-159.
Review
For citations:
Gelis L.G., Medvedeva E.A., Russkih I.I. Prevalence and Clinical Significance of high Residual Platelet Reactivity in Patients with Unstable Angina. Emergency Cardiology and Cardiovascular Risks journal. 2017;1(1):57-64. (In Russ.)
Views:
13
Email this article 